Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate
Zevra reported progress in 2023, including results from a phase 2 study for idiopathic hypersomnia and plans to expand into narcolepsy.
Source: sleepreviewmag.com
Neilf Mcfarlane News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Neilf Mcfarlane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Neilf Mcfarlane Today - Breaking & Trending Today
Zevra Therapeutics Appoints Global Medical Leader, Adrian
CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics...
Source: globenewswire.com
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
20.11.2023 - Acquisition includes OLPRUVA, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra into commercial stage, diversifying its revenue and providing scale Settlement of Acer’s warrant obligations through direct transaction ... Seite 1
Source: wallstreet-online.de
KP1077 for IH and Narcolepsy a Priority for Zevra
Zevra Therapeutics named KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Source: sleepreviewmag.com
Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results
Net Revenue of $2.9M and Cash Runway into 2026
Source: yahoo.com